Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1128688 dose-response study in symptomatic endometriosis
NL-OMON46660Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAY1128688 in endometriosis, sponsored by Bayer. Primary endpoint: Primary objective. Started Mar 2018; status: active, not recruiting.
02
Drugs
BAY1128688
03
Conditions
endometriosis
Beyond the preview
Go deeper on NL-OMON46660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46660.